CEBPA and acute myeloid leukemia: The European LeukemiaNet revised the prognostic model for AML in 2017 to add mutations in RUNX1 and ASXL1 to the previously identified molecular risk categories defined by mutations in NPM1, CEBPA, FLT3–ITD and TP53. This model stratifies AML patients into three prognostic groups (good, intermediate and poor risk).